Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retinal Edema Clear all
Completed Phase 2 Interventional

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

NCT03071055
View directory record Official record
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab Injection [Lucentis]
Drug
Lead sponsor
Southeast Clinical Research Associates, LLC
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Charlotte, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Not applicable Interventional

Long Term Safety of Cooling Anesthesia for Intravitreal Injection

NCT03956797
View directory record Official record
Conditions
Anesthesia, Local, Intravitreal Injection, Macular Edema, Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Recens Cooling Anesthesia Device
Device
Lead sponsor
Recens Medical, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Reno, Nevada • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Not applicable Interventional

30g vs 33g Needle for Intravitreal Injections

NCT03038048
View directory record Official record
Conditions
Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Varying needle size with intravitreal ranibizumab or aflibercept
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Jul 22, 2026, 5:05 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

PST/Laser v. Laser Alone for CSME

NCT00229918
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
triamcinolone acetonide
Drug
Lead sponsor
Edward Hines Jr. VA Hospital
Federal
Eligibility
25 Years to 80 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2005 · Synced Jul 22, 2026, 5:05 PM EDT
Completed No phase listed Observational Results available

Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

NCT01411696
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
dexamethasone intravitreal implant 0.7 mg
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Jul 22, 2026, 5:05 PM EDT
Completed No phase listed Observational

Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)

NCT02420132
View directory record Official record
Conditions
Macular Edema, Macular Degeneration
Interventions
Ranibizumab
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF

NCT01946399
View directory record Official record
Conditions
Retinal Vein Occlusion (RVO), Macular Edema
Interventions
Ozurdex implant
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Jul 22, 2026, 5:05 PM EDT
Available No phase listed Expanded access

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

NCT01487044
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Macugen (Pegaptanib Sodium)
Drug
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Near-infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study

NCT00846092
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Warp 10 LED Device, Near-infrared light (NIR)
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Jul 22, 2026, 5:05 PM EDT
Not listed Phase 2 Interventional

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

NCT05393284
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Interventions
OPL-0401 Dose 1, Placebo
Drug
Lead sponsor
Valo Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
25
States / cities
Mountain View, California • Riverside, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema

NCT00069056
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Laser Treatment
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Phase 3 Interventional Results available

PROMINENT-Eye Ancillary Study (Protocol AD)

NCT03345901
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Pemafibrate, Placebo
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Phoenix, Arizona • Campbell, California • Glendale, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 22, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

NCT01918371
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Anti-VEGF
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema

NCT00444600
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Triamcinolone Acetonide + laser, Ranibizumab + laser, Sham injection + laser, Ranibizumab + deferred laser
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
50
States / cities
Artesia, California • Beverly Hills, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 4 Interventional

Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.

NCT01244334
View directory record Official record
Conditions
Cataracts, Corneal Edema, Retinal Structural Change, Deposit and Degeneration, Visual Acuity Reduced Transiently
Interventions
Difluprednate ophthalmic emulsion 0.05%, Prednisolone acetate 1%
Drug
Lead sponsor
Edward J. Holland
Other
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Edgewood, Kentucky • Lynbrook, New York • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Jul 22, 2026, 5:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

NCT07218770
View directory record Official record
Conditions
Active Noninfectious Uveitis Affecting the Posterior Segment
Interventions
REGN7041
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Sacramento, California • Oak Park, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated No phase listed Observational

Epiretinal Membrane and Pseudophakic Cystoid Macular Edema

NCT02693353
View directory record Official record
Conditions
Macular Edema, Epiretinal Membrane
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cool vs Room-temperature Artificial Tears

NCT05832996
View directory record Official record
Conditions
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
Interventions
Refresh Plus Preservative-free Lubricant Eye Drops
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 105 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
pegaptanib sodium (Macugen)
Drug
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment

NCT00543296
View directory record Official record
Conditions
Uveitis
Interventions
0.59 mg Fluocinolone Acetonide implant
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

NCT02255032
View directory record Official record
Conditions
Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
Interventions
4 mg CLS-TA, 0.8 mg CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Jul 22, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)

NCT00668785
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Jumper, J. Michael, M.D.
Individual
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers

NCT00414999
View directory record Official record
Conditions
Macular Degeneration, Diabetic Retinopathy
Interventions
TG100801
Drug
Lead sponsor
TargeGen
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2007 · Synced Jul 22, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

NCT06599684
View directory record Official record
Conditions
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema, Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions
INV-102
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 22, 2026, 5:05 PM EDT